New hope drug enters first human tests for tough cancers
NCT ID NCT07224425
Summary
This is the first study in people testing a new drug called BI 3810944 for adults with advanced solid tumors or melanoma that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug helps shrink tumors. Participants will receive the drug every three weeks and be closely monitored for side effects and tumor response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology, PLLC - Elliston Place Plaza DDU
Nashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
Leuven, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Louisville
Louisville, Kentucky, 40202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.